Summary of Purpose
The purpose of this study is to determine if YM872 in combination with t-PA can reduce disability and brain damage from stroke. YM872 or placebo will be given as a continuous intravenous (iv) infusion for 24 hours. It is important that the study medication, YM872 or placebo, is administered prior to the completion of the t-PA administration. The clinical effects of YM872 in addition to t-PA will be determined...Read More →
The following dates are available for this trial. Trial information last updated on 31 March 2006.
|1 Dec 2000||16 Aug 2002||Unavailable||1 Jan 2003||1 Mar 2006||Unavailable|
|Start Date||First Received||1st Completion||Completion||Verification||Results|
- Allocation: Randomized
- Masking: Double-Blind
- Purpose: Treatment